Skip to content

Study · Animal study (in vivo) · mouse · 2014

5 results

New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Merenlender-Wagner A, Shemer Z, Touloumi O, Lagoudaki R, Giladi E, Andrieux A, Grigoriadis NC, Gozes I

Autophagy1 Jan 2014Cited by 73 (Europe PMC)

PMID25484074 (opens in a new tab)PMCIDPMC4502702 (opens in a new tab)DOI10.4161/15548627.2014.984274 (opens in a new tab)PepBankPUB-25484074
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In Map6-deficient mice, NAP reversed decreased hippocampal Becn1 mRNA, whereas clozapine did not.

    In plain wordsIn Map6-deficient mice, NAP reversed reduced hippocampal Becn1 mRNA, whereas clozapine did not.

    Peptide
    Davunetide
    Outcome
    IncreaseHippocampal Becn1 mRNA
    Study

    mousen: not reported in source

    Map6-deficient mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, for the first time, we reveal significant decreases in hippocampal Becn1 mRNA and reversal by NAP but not by the antipsychotic clozapine (CLZ) in Map6-deficient (Map6(+/-)) mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Map6-deficient mice, NAP protected against hyperlocomotion.

    In plain wordsIn Map6-deficient mice, NAP protected against excessive movement.

    Peptide
    Davunetide
    Outcome
    DecreaseHyperlocomotion
    Study

    mousen: not reported in source

    Map6-deficient mice
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Normalization of Becn1 expression by NAP was coupled with behavioral protection against hyperlocomotion and cognitive deficits measured in the object recognition test.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Map6-deficient mice, NAP protected against cognitive deficits in the object recognition test.

    In plain wordsIn Map6-deficient mice, NAP protected against object recognition deficits.

    Peptide
    Davunetide
    Outcome
    DecreaseObject recognition deficits
    Study

    mousen: not reported in source

    Map6-deficient mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Normalization of Becn1 expression by NAP was coupled with behavioral protection against hyperlocomotion and cognitive deficits measured in the object recognition test.
  4. 04LabOther designMechanism

    NAP enhanced the ADNP-LC3B interaction in the reported molecular interaction study.

    In plain wordsIn lab tests, NAP enhanced the interaction between ADNP and LC3B.

    Peptide
    Davunetide
    Outcome
    IncreaseADNP-LC3B interaction
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The drug candidate NAP (davunetide), a peptide fragment from ADNP, enhanced the ADNP-LC3B interaction.

Studies that did not test the peptide alone1

In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Davunetide.

  1. 05AnimalNot a test of Davunetide aloneAnimal study (in vivo)Efficacy outcome

    In Map6-deficient mice, combined clozapine and NAP normalized behavioral outcomes.

    In plain wordsIn Map6-deficient mice, combined clozapine and NAP normalized behavioral outcomes.

    Peptide
    Davunetide
    Outcome
    Direction not reportedBehavioral outcomes with combination treatment
    Study

    mousen: not reported in source

    Map6-deficient mice
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    The combination of CLZ and NAP resulted in normalized outcome behaviors.

    In this study, Davunetide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Davunetide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.